New publication strengthens Neogap's patented technology showing that it also can be used for proliferation of T cells from blood
NEOGAP Therapeutics, which develops individualised immunotherapy for cancer treatment, presents in a publication with researchers at Karolinska Institutet preclinical data that further proves the capability of the company's proprietary technology EpiTCer® to produce tumour-specific T cells. The evaluations were performed with blood as the starting material and the results also show that T cells produced with EpiTCer® are more effective in eliminating tumour cells compared to alternative methods based on stimulation with peptides or tumour extracts.Cancer is caused by genetic changes in